XTX Topco Ltd Has $58,000 Stock Position in PDS Biotechnology Co. (NASDAQ:PDSB)

XTX Topco Ltd lowered its position in shares of PDS Biotechnology Co. (NASDAQ:PDSB) by 67.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,654 shares of the company’s stock after selling 40,600 shares during the quarter. XTX Topco Ltd owned approximately 0.05% of PDS Biotechnology worth $58,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Kathleen S. Wright Associates Inc. bought a new stake in PDS Biotechnology during the 1st quarter worth about $28,000. Tempus Wealth Planning LLC bought a new position in shares of PDS Biotechnology in the 2nd quarter valued at about $55,000. Ground Swell Capital LLC bought a new position in shares of PDS Biotechnology in the 2nd quarter valued at about $67,000. Blair William & Co. IL boosted its stake in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after purchasing an additional 81,743 shares during the last quarter. Finally, Inspirion Wealth Advisors LLC boosted its stake in shares of PDS Biotechnology by 5.5% in the 1st quarter. Inspirion Wealth Advisors LLC now owns 354,977 shares of the company’s stock valued at $1,406,000 after purchasing an additional 18,383 shares during the last quarter. Institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Stock Performance

Shares of NASDAQ:PDSB opened at $4.11 on Thursday. The company has a market capitalization of $150.75 million, a price-to-earnings ratio of -3.02 and a beta of 1.88. The firm’s 50 day simple moving average is $3.25 and its 200 day simple moving average is $3.35. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. PDS Biotechnology Co. has a fifty-two week low of $2.53 and a fifty-two week high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.08. During the same quarter last year, the company earned ($0.37) earnings per share. As a group, sell-side analysts forecast that PDS Biotechnology Co. will post -1.3 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on PDSB shares. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research note on Wednesday. B. Riley reduced their target price on shares of PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. Finally, Alliance Global Partners raised shares of PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, PDS Biotechnology has an average rating of “Moderate Buy” and an average price target of $14.25.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.